English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Alzheimer’s disease is a very common type of dementia that triggers memory loss and impedes other important mental functions [1,2]. It is a neurodegenerative disorder which affects over 5 million people in the United States alone [13].In fact, it is the 6th leading cause of death in the United States, and on average, an American is diagnosed with Alzheimer’s disease every 66 seconds [1,3]. This can be a familial or sporadic disease which is primarily caused by the destruction of neurons which starts from the hippocampus and spreads throughout the brain (cerebellum is spared) [4]. The apoptosis of the countless neurons seems to be caused by a multitude of factors including amyloidbeta plaques, Tau tangles, and neuronal loss [1,2]. For the purposes of this investigation, there will be a primary focus on the amyloid-beta plaques because the buildup of neurotoxic plaques on the neurons seems to be a key factor in Alzheimer’s disease [1,2]. Enzymes called γ-secretase and β-secretase cleave a protein called an amyloid precursor protein (APP) to form these amyloid-beta peptides which can accumulate and form neurotoxic plaques [5,6]. Previous studies have found that DAPT (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester), a dipeptide analogue, is effective in inhibiting γ-secretase thus decreasing amyloid-beta concentration in the brain [6]. This study confirms the efficacy of DAPT in inhibiting γ-secretase, but also investigates the alternative inhibitory effects of drugs like Activase® rt-PA (alteplase), a tissue plasminogen activator typically used for treatment of stroke, and clonazepam (E64), a pill used to treat panic disorder and anxiety. Although the goal of this research was to observe the effects on both Aβ40 (40 amino acid amyloid-beta chain) and Aβ42 (42 amino acid amyloid-beta chain) production, only the effects of Aβ40 production were examined due to possible contamination in the Aβ42 tests.

Contrasting the Effects of Alteplase and DAPT on the Cleavage of C-Terminal Fragments and Amyloid-β Concentration